Rhythm Pharmaceuticals, Inc.
HealthcareNASDAQ:RYTM · NASDAQ Global Market
+$0.72 today
Vol 0.55M · Avg 0.80M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$217.2M of revenue converted into -$202.7M of net income for the selected period. Gross margin is 89.4% and net margin is -93.7%, showing how much revenue survives after costs and taxes. EPS is $-3.13, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $189.8M +45.8% | $130.1M +68.1% | $77.4M +227.6% | $23.6M +649.5% | $3.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $19.5M +45.8% | $13.4M +43.7% | $9.3M +336.1% | $2.1M +256.1% | $599.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $170.3M +45.8% | $116.8M +71.4% | $68.1M +216.8% | $21.5M +741.7% | $2.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 89.7% +0.0pp | 89.7% +1.7pp | 88.0% -3.0pp | 91.0% +10.0pp | 81.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $167.3M -29.7% | $238.0M +76.3% | $135.0M +24.2% | $108.6M +4.3% | $104.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $194.9M +35.1% | $144.3M +22.8% | $117.5M +27.7% | $92.0M +34.4% | $68.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $362.3M -5.2% | $382.3M +51.4% | $252.5M +25.8% | $200.7M +16.2% | $172.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.3M -14.4% | $1.6M -11.1% | $1.8M +5.1% | $1.7M +44.4% | $1.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$174.1M +26.9% | -$238.1M -41.3% | -$168.5M +3.3% | -$174.2M -154.5% | -$68.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -91.8% +91.2pp | -183.0% +34.6pp | -217.6% +519.6pp | -737.1% +1433.2pp | -2170.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$192.0M +27.7% | -$265.5M -44.0% | -$184.4M -2.9% | -$179.2M -5.3% | -$170.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -101.2% +102.8pp | -204.0% +34.1pp | -238.1% +519.8pp | -757.9% +4633.9pp | -5391.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $15.3M +4.0% | $14.7M +5.5% | $13.9M +246.1% | $4.0M +801.3% | $447.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $20.6M -0.1% | $20.6M +48.3% | $13.9M +167.1% | $5.2M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.0M -176.7% | $5.2M +2059.3% | $243.0K +112.4% | -$2.0M -102.0% | $100.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$196.0M +24.7% | -$260.3M -41.4% | -$184.1M -1.7% | -$181.1M -160.2% | -$69.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -103.3% +96.7pp | -200.0% +37.8pp | -237.8% +528.4pp | -766.2% +1440.9pp | -2207.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $497.0K +43.6% | $346.0K -38.7% | $564.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$196.5M +24.6% | -$260.6M -41.1% | -$184.7M -2.0% | -$181.1M -160.2% | -$69.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -103.6% +96.7pp | -200.3% +38.2pp | -238.5% +527.7pp | -766.2% +1440.9pp | -2207.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +28.3% | -$4 -35.6% | -$3 +8.8% | -$4 -156.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +28.3% | -$4 -35.6% | -$3 +8.8% | -$4 -156.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $65.0M +6.5% | $61.0M +5.8% | $57.7M +10.7% | $52.1M +5.1% | $49.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $65.0M +6.5% | $61.0M +5.8% | $57.7M +10.7% | $52.1M +5.1% | $49.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Arcellx, Inc.
ACLX
$6.73B
Akero Therapeutics, Inc.
AKRO
$4.50B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.86B
uniQure N.V.
NASDAQ:QURE
$1.74B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Ventyx Biosciences, Inc.
VTYX
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Inozyme Pharma, Inc.
INZY
$258.25M
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$100.28M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RYTM generate?
Rhythm Pharmaceuticals, Inc. (RYTM) reported $189.76M of revenue in fiscal 2025.
Is RYTM profitable?
Rhythm Pharmaceuticals, Inc. (RYTM) reported -$196,539,000.00 of net income, with a net margin of -103.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.